{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05567562",
            "orgStudyIdInfo": {
                "id": "2022P002327"
            },
            "secondaryIdInfos": [
                {
                    "id": "K23HL141651",
                    "type": "NIH",
                    "link": "https://reporter.nih.gov/quickSearch/K23HL141651"
                }
            ],
            "organization": {
                "fullName": "Brigham and Women's Hospital",
                "class": "OTHER"
            },
            "briefTitle": "Anti-Platelets in Chronic Obstructive Pulmonary Disease",
            "officialTitle": "Dual Anti-platelet Therapy in Chronic Obstructive Pulmonary Disease Study",
            "therapeuticArea": [
                "Respiratory",
                "Other"
            ],
            "study": "anti-platelets-in-chronic-obstructive-pulmonary-disease"
        },
        "statusModule": {
            "statusVerifiedDate": "2023-12",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-12-08",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-12-01",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-06-01",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2022-10-03",
            "studyFirstSubmitQcDate": "2022-10-03",
            "studyFirstPostDateStruct": {
                "date": "2022-10-05",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2023-12-08",
            "lastUpdatePostDateStruct": {
                "date": "2023-12-15",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "PRINCIPAL_INVESTIGATOR",
                "investigatorFullName": "Carrie Pistenmaa, M.D",
                "investigatorTitle": "Assistant Professor",
                "investigatorAffiliation": "Brigham and Women's Hospital"
            },
            "leadSponsor": {
                "name": "Brigham and Women's Hospital",
                "class": "OTHER"
            },
            "collaborators": [
                {
                    "name": "National Heart, Lung, and Blood Institute (NHLBI)",
                    "class": "NIH"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false,
            "isUsExport": false
        },
        "descriptionModule": {
            "briefSummary": "This is a 6 week crossover study in former smokers with and without COPD to evaluate whether 2 weeks of dual antiplatelet therapy (aspirin 81mg and clopidogrel 75mg) improves pulmonary perfusion (i.e. blood flow in the lungs measured on a contrast CT scan) compared to placebo.",
            "detailedDescription": "This is a single-center Phase IIa randomized double-blind crossover study in smokers with and without chronic obstructive pulmonary disease (COPD) to test whether dual antiplatelet therapy (aspirin 81mg and clopidogrel 75mg) improves pulmonary perfusion (i.e. blood flow in the lungs) compared to placebo.\n\nWe will enroll 30 subjects (20 with COPD, 10 without) who will each take part for 6 weeks. Participants and researchers will be blinded, they will not know which medications they are on first. Each participant will be asked to take aspirin and clopidogrel together for 2 weeks and also matching placebos for 2 weeks, with a 2 week washout period in between. Pulmonary blood flow will be evaluated with a contrast-enhanced CT scan of the chest two times over the 6 week study."
        },
        "conditionsModule": {
            "conditions": [
                "COPD",
                "Emphysema",
                "Emphysema or COPD"
            ],
            "keywords": [
                "Platelet Dysfunction",
                "Pulmonary Blood Vessel Injury",
                "COPD",
                "Emphysema"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "CROSSOVER",
                "interventionModelDescription": "Double-blind crossover study is a Phase 2 interventional study to assess whether dual-anti platelet therapy improves pulmonary blood flow compared to placebo",
                "primaryPurpose": "OTHER",
                "maskingInfo": {
                    "masking": "QUADRUPLE",
                    "maskingDescription": "All participants, investigators and care providers will be blinded as to dual-anti platelet therapy or placebo treatment",
                    "whoMasked": [
                        "PARTICIPANT",
                        "CARE_PROVIDER",
                        "INVESTIGATOR",
                        "OUTCOMES_ASSESSOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 30,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "COPD Cases: Dual antiplatelet therapy first, then placebo",
                    "type": "EXPERIMENTAL",
                    "description": "Dual antiplatelet therapy (aspirin 81mg and clopidogrel 75mg) will be given for 2 weeks, followed by 2 weeks without intervention, then 2 weeks of placebo",
                    "interventionNames": [
                        "Combination Product: dual anti-platelet therapy",
                        "Drug: Placebo"
                    ]
                },
                {
                    "label": "COPD Cases: Placebo first, then dual antiplatelet therapy",
                    "type": "PLACEBO_COMPARATOR",
                    "description": "Placebos for each therapy (2 pills) will be given for 2 weeks, followed by 2 weeks without intervention, then 2 weeks of dual antiplatelet therapy",
                    "interventionNames": [
                        "Combination Product: dual anti-platelet therapy",
                        "Drug: Placebo"
                    ]
                },
                {
                    "label": "Controls: Dual antiplatelet therapy first, then placebo",
                    "type": "ACTIVE_COMPARATOR",
                    "description": "Dual antiplatelet therapy (aspirin 81mg and clopidogrel 75mg) will be given for 2 weeks, followed by 2 weeks without intervention, then 2 weeks of placebo",
                    "interventionNames": [
                        "Combination Product: dual anti-platelet therapy",
                        "Drug: Placebo"
                    ]
                },
                {
                    "label": "Controls: Placebo first, then dual antiplatelet therapy",
                    "type": "PLACEBO_COMPARATOR",
                    "description": "Placebos for each therapy (2 pills) will be given for 2 weeks, followed by 2 weeks without intervention, then 2 weeks of dual antiplatelet therapy",
                    "interventionNames": [
                        "Combination Product: dual anti-platelet therapy",
                        "Drug: Placebo"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "COMBINATION_PRODUCT",
                    "name": "dual anti-platelet therapy",
                    "description": "dual anti-platelet therapy",
                    "armGroupLabels": [
                        "COPD Cases: Dual antiplatelet therapy first, then placebo",
                        "COPD Cases: Placebo first, then dual antiplatelet therapy",
                        "Controls: Dual antiplatelet therapy first, then placebo",
                        "Controls: Placebo first, then dual antiplatelet therapy"
                    ],
                    "otherNames": [
                        "aspirin 81mg EC tab",
                        "clopidogrel 75mg tab"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Placebo",
                    "description": "Placebo",
                    "armGroupLabels": [
                        "COPD Cases: Dual antiplatelet therapy first, then placebo",
                        "COPD Cases: Placebo first, then dual antiplatelet therapy",
                        "Controls: Dual antiplatelet therapy first, then placebo",
                        "Controls: Placebo first, then dual antiplatelet therapy"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Pulmonary microvascular blood volume, CV",
                    "description": "Coefficient of variation (CV) of pulmonary microvascular blood volume on dual energy CT scan, comparing on dual antiplatelet therapy to placebo",
                    "timeFrame": "6 weeks"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Pulmonary microvascular blood volume",
                    "description": "Pulmonary microvascular blood volume on dual energy CT scan, comparing on dual antiplatelet therapy to placebo",
                    "timeFrame": "6 weeks"
                },
                {
                    "measure": "Pulmonary microvascular blood flow, CV",
                    "description": "Coefficient of variation (CV) of pulmonary microvascular blood flow on dual energy CT scan, comparing on dual antiplatelet therapy to placebo",
                    "timeFrame": "6 weeks"
                },
                {
                    "measure": "Pulmonary microvascular blood flow",
                    "description": "Pulmonary microvascular blood flow on dual energy CT scan, comparing on dual antiplatelet therapy to placebo",
                    "timeFrame": "6 weeks"
                },
                {
                    "measure": "Diffusing capacity",
                    "description": "DLCO",
                    "timeFrame": "6 weeks"
                },
                {
                    "measure": "Oxygen saturation",
                    "description": "Resting oxygen saturation",
                    "timeFrame": "6 weeks"
                }
            ],
            "otherOutcomes": [
                {
                    "measure": "Vascular pruning on CT",
                    "description": "Distal macrovascular pruning on non-contrast inspiratory CT",
                    "timeFrame": "6 weeks"
                },
                {
                    "measure": "Percent emphysema on CT",
                    "description": "Percent emphysema-950 on non-contrast inspiratory CT",
                    "timeFrame": "6 weeks"
                },
                {
                    "measure": "Functional small airways disease on CT",
                    "description": "Functional small airways disease, calculated from gas trapping on non-contrast expiratory and inspiratory CT",
                    "timeFrame": "6 weeks"
                },
                {
                    "measure": "Lung function",
                    "description": "Spirometry measures of forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC) and FEV1/FVC",
                    "timeFrame": "6 weeks"
                },
                {
                    "measure": "Plasma biomarkers",
                    "description": "Biomarkers related to endothelial activation (sICAM-1, sVCAM-1, sP-selectin, sE-selectin, vWF), angiogenesis (VEGF, TIMP-1 and PAI-1) and inflammation (WBC, CRP, IL-6, TNF-a, myeloperoxidase).",
                    "timeFrame": "6 weeks"
                },
                {
                    "measure": "Platelet activation measures",
                    "description": "Platelet activation measures by flow cytometry: circulating monocyte-platelet aggregates (unstimulated), activated GPIIb/IIIa receptor, unstimulated, and stimulated by low and high dose arachidonic acid and adenosine diphosphate, and P-selectin on the platelet surface, unstimulated, and stimulated by low and high dose arachidonic acid and adenosine diphosphate. Also urine 11d-TXB2, plasma TXB2 and aspirin-triggered lipoxin A4",
                    "timeFrame": "6 weeks"
                },
                {
                    "measure": "FeNO",
                    "description": "Fraction of exhaled nitric oxide",
                    "timeFrame": "6 weeks"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria - COPD Cases:\n\n* COPD (FEV1/FVC \\< 0.7, FVC \\>= 80%), GOLD Stage I/II (FEV1 \\>= 50%)\n* Evidence of visual emphysema (centrilobular emphysema or panlobular emphysema) on prior CT scan\n* Former smoker at least 10 pack years\n\nInclusion Criteria - Controls:\n\n* Normal lung function (FEV1/FVC \\> 0.7, FEV1 and FVC \\>= 80%)\n* No evidence of visual emphysema on prior CT scan\n* Former smoker at least 10 pack years\n\nExclusion Criteria:\n\n* Platelet count \\< 150,000/dL or self-report of a bleeding disorder;\n* Regular use of aspirin, clopidogrel or another antiplatelet medication;\n* Allergy to aspirin, clopidogrel, albuterol or IV contrast;\n* BMI \\> 35;\n* History of intracranial hemorrhage, severe GI bleed or other life-threatening bleed;\n* Use of blood thinner (e.g. warfarin, lovenox or novel oral anti-coagulants);\n* Use of supplemental oxygen at home, other than only nocturnal use;\n* Regular use of an NSAID;\n* Daily use of oral steroids, theophylline, roflumilast, or diuretics;\n* History of organ transplant or autoimmune disease (rheumatoid arthritis, lupus);\n* Use of a biologic medication with regular injections;\n* Other current lung disease (interstitial lung disease, idiopathic pulmonary fibrosis, asthma);\n* IV drug use within the last year;\n* History of lung surgery to remove part of the lung;\n* Chest CT scan within 5 years showing significant lung mass, infiltrate (ground glass or other consolidation), or scarring/fibrosis of the lungs;\n* Bullae or advanced destructive emphysema in more than 1/3 of the lungs;\n* Treatment for cancer within the last 12 months;\n* Known diagnosis of pulmonary hypertension;\n* Known systolic heart failure (RV or LV EF \\< 40%);\n* Use of medications for diabetes (metformin, januvia, insulin, etc);\n* Acute or chronic renal insufficiency (estimated glomerular filtration rate \\[GFR\\] \\<60 mL/min/1.73 m2 or self-report). GFR will be calculated using the CKD-EPI equation;\n* Current or planned pregnancy in the next year;\n* Allergy to iodine contrast;\n* Use of tobacco products (cigarettes, cigars or pipes) or E-cigarettes within 1 year;\n* Regular marijuana smoking;\n* Exacerbation of respiratory symptoms within the previous 6 weeks, such as that requiring hospitalization, oral prednisone or antibiotics to control symptoms, or longer and not yet returned to baseline; and\n* Chest, abdominal or eye surgery, or a heart attack or stroke, within the last 3 months.",
            "healthyVolunteers": true,
            "sex": "ALL",
            "minimumAge": "50 Years",
            "maximumAge": "75 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Carrie L Pistenmaa, MD, MS",
                    "role": "CONTACT",
                    "phone": "617-732-8201",
                    "email": "arc@partners.org"
                },
                {
                    "name": "Maria A Cinelli",
                    "role": "CONTACT",
                    "phone": "617-732-8201",
                    "email": "arc@partners.org"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Carrie L Pistenmaa, MD, MS",
                    "affiliation": "Brigham and Women's Hospital",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Brigham and Women's Hospital",
                    "status": "RECRUITING",
                    "city": "Boston",
                    "state": "Massachusetts",
                    "zip": "02115",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Carrie Pistenmaa, MD, MS",
                            "role": "CONTACT",
                            "phone": "617-732-8201",
                            "email": "arc@partners.org"
                        }
                    ],
                    "geoPoint": {
                        "lat": 42.35843,
                        "lon": -71.05977
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO",
            "description": "This is a small single-center study, we do not plan to share participant level data"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000029424",
                    "term": "Pulmonary Disease, Chronic Obstructive"
                },
                {
                    "id": "D000008173",
                    "term": "Lung Diseases, Obstructive"
                },
                {
                    "id": "D000011656",
                    "term": "Pulmonary Emphysema"
                },
                {
                    "id": "D000004646",
                    "term": "Emphysema"
                }
            ],
            "ancestors": [
                {
                    "id": "D000008171",
                    "term": "Lung Diseases"
                },
                {
                    "id": "D000012140",
                    "term": "Respiratory Tract Diseases"
                },
                {
                    "id": "D000002908",
                    "term": "Chronic Disease"
                },
                {
                    "id": "D000020969",
                    "term": "Disease Attributes"
                },
                {
                    "id": "D000010335",
                    "term": "Pathologic Processes"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M11168",
                    "name": "Lung Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M7812",
                    "name": "Emphysema",
                    "asFound": "Emphysema",
                    "relevance": "HIGH"
                },
                {
                    "id": "M11170",
                    "name": "Lung Diseases, Obstructive",
                    "asFound": "Obstructive Pulmonary Disease",
                    "relevance": "HIGH"
                },
                {
                    "id": "M23449",
                    "name": "Pulmonary Disease, Chronic Obstructive",
                    "asFound": "Chronic Obstructive Pulmonary Disease",
                    "relevance": "HIGH"
                },
                {
                    "id": "M28858",
                    "name": "Vascular System Injuries",
                    "relevance": "LOW"
                },
                {
                    "id": "M14510",
                    "name": "Pulmonary Emphysema",
                    "asFound": "Emphysema",
                    "relevance": "HIGH"
                },
                {
                    "id": "M14977",
                    "name": "Respiratory Tract Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M6147",
                    "name": "Chronic Disease",
                    "relevance": "LOW"
                },
                {
                    "id": "M22700",
                    "name": "Disease Attributes",
                    "relevance": "LOW"
                },
                {
                    "id": "T1303",
                    "name": "Chronic Graft Versus Host Disease",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC08",
                    "name": "Respiratory Tract (Lung and Bronchial) Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "BC14",
                    "name": "Heart and Blood Diseases"
                },
                {
                    "abbrev": "BC26",
                    "name": "Wounds and Injuries"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000077144",
                    "term": "Clopidogrel"
                }
            ],
            "ancestors": [
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000010975",
                    "term": "Platelet Aggregation Inhibitors"
                },
                {
                    "id": "D000058921",
                    "term": "Purinergic P2Y Receptor Antagonists"
                },
                {
                    "id": "D000058919",
                    "term": "Purinergic P2 Receptor Antagonists"
                },
                {
                    "id": "D000058914",
                    "term": "Purinergic Antagonists"
                },
                {
                    "id": "D000058905",
                    "term": "Purinergic Agents"
                },
                {
                    "id": "D000018377",
                    "term": "Neurotransmitter Agents"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M1669",
                    "name": "Clopidogrel",
                    "asFound": "Services",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4548",
                    "name": "Aspirin",
                    "relevance": "LOW"
                },
                {
                    "id": "M13865",
                    "name": "Platelet Aggregation Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M29294",
                    "name": "Purinergic P2Y Receptor Antagonists",
                    "relevance": "LOW"
                },
                {
                    "id": "M20504",
                    "name": "Neurotransmitter Agents",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "PlAggInh",
                    "name": "Platelet Aggregation Inhibitors"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "Antipy",
                    "name": "Antipyretics"
                },
                {
                    "abbrev": "Infl",
                    "name": "Anti-Inflammatory Agents"
                },
                {
                    "abbrev": "ARhu",
                    "name": "Antirheumatic Agents"
                },
                {
                    "abbrev": "FiAg",
                    "name": "Fibrinolytic Agents"
                },
                {
                    "abbrev": "Analg",
                    "name": "Analgesics"
                }
            ]
        }
    },
    "hasResults": false
}